vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $93.5M, roughly 1.8× COMSCORE, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -1.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.8%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
ESPR vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $93.5M |
| Net Profit | — | $3.0M |
| Gross Margin | — | 41.0% |
| Operating Margin | 50.6% | 7.0% |
| Net Margin | — | 3.2% |
| Revenue YoY | 143.7% | -1.5% |
| Net Profit YoY | — | -3.7% |
| EPS (diluted) | $0.32 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $93.5M | ||
| Q3 25 | $87.3M | $88.9M | ||
| Q2 25 | $82.4M | $89.4M | ||
| Q1 25 | $65.0M | $85.7M | ||
| Q4 24 | $69.1M | $94.9M | ||
| Q3 24 | $51.6M | $88.5M | ||
| Q2 24 | $73.8M | $85.8M | ||
| Q1 24 | $137.7M | $86.8M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | $-31.3M | $453.0K | ||
| Q2 25 | $-12.7M | $-9.5M | ||
| Q1 25 | $-40.5M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-29.5M | $-60.6M | ||
| Q2 24 | $-61.9M | $-1.7M | ||
| Q1 24 | $61.0M | $-1.1M |
| Q4 25 | — | 41.0% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 40.6% | ||
| Q1 25 | — | 39.6% | ||
| Q4 24 | — | 42.4% | ||
| Q3 24 | — | 41.2% | ||
| Q2 24 | — | 39.5% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | 50.6% | 7.0% | ||
| Q3 25 | -11.4% | 1.9% | ||
| Q2 25 | 8.6% | -1.9% | ||
| Q1 25 | -34.0% | -2.4% | ||
| Q4 24 | -6.4% | 4.1% | ||
| Q3 24 | -31.0% | -67.4% | ||
| Q2 24 | 3.5% | -2.2% | ||
| Q1 24 | 52.5% | -2.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | -35.9% | 0.5% | ||
| Q2 25 | -15.4% | -10.6% | ||
| Q1 25 | -62.2% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -57.2% | -68.5% | ||
| Q2 24 | -83.9% | -2.0% | ||
| Q1 24 | 44.3% | -1.2% |
| Q4 25 | $0.32 | $9.50 | ||
| Q3 25 | $-0.16 | $-0.86 | ||
| Q2 25 | $-0.06 | $-2.73 | ||
| Q1 25 | $-0.21 | $-1.66 | ||
| Q4 24 | $-0.14 | $-0.47 | ||
| Q3 24 | $-0.15 | $-12.79 | ||
| Q2 24 | $-0.33 | $-1.19 | ||
| Q1 24 | $0.34 | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $23.6M |
| Total DebtLower is stronger | — | $41.5M |
| Stockholders' EquityBook value | $-302.0M | $111.4M |
| Total Assets | $465.9M | $407.7M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $23.6M | ||
| Q3 25 | $92.4M | $26.7M | ||
| Q2 25 | $86.1M | $26.0M | ||
| Q1 25 | $114.6M | $31.0M | ||
| Q4 24 | $144.8M | $29.9M | ||
| Q3 24 | $144.7M | $20.0M | ||
| Q2 24 | $189.3M | $14.7M | ||
| Q1 24 | $226.6M | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $111.4M | ||
| Q3 25 | $-451.4M | $-26.3M | ||
| Q2 25 | $-433.5M | $-21.7M | ||
| Q1 25 | $-426.2M | $-13.5M | ||
| Q4 24 | $-388.7M | $-8.3M | ||
| Q3 24 | $-370.2M | $-2.7M | ||
| Q2 24 | $-344.2M | $45.8M | ||
| Q1 24 | $-294.3M | $51.4M |
| Q4 25 | $465.9M | $407.7M | ||
| Q3 25 | $364.0M | $406.9M | ||
| Q2 25 | $347.1M | $415.9M | ||
| Q1 25 | $324.0M | $421.5M | ||
| Q4 24 | $343.8M | $430.2M | ||
| Q3 24 | $314.1M | $412.5M | ||
| Q2 24 | $352.3M | $474.1M | ||
| Q1 24 | $373.1M | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $3.2M |
| Free Cash FlowOCF − Capex | — | $2.9M |
| FCF MarginFCF / Revenue | — | 3.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | — | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $3.2M | ||
| Q3 25 | $-4.3M | $9.5M | ||
| Q2 25 | $-31.4M | $932.0K | ||
| Q1 25 | $-22.6M | $9.1M | ||
| Q4 24 | $-35.0M | $-10.0M | ||
| Q3 24 | $-35.3M | $12.5M | ||
| Q2 24 | $-7.2M | $8.7M | ||
| Q1 24 | $53.8M | $6.9M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $9.4M | ||
| Q2 25 | — | $787.0K | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | $-35.5M | $12.4M | ||
| Q2 24 | $-7.3M | $8.5M | ||
| Q1 24 | $53.8M | $6.6M |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 10.5% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 10.1% | ||
| Q4 24 | — | -10.8% | ||
| Q3 24 | -68.7% | 14.0% | ||
| Q2 24 | -9.9% | 10.0% | ||
| Q1 24 | 39.0% | 7.6% |
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.1% | 0.2% | ||
| Q1 24 | 0.1% | 0.3% |
| Q4 25 | — | 1.07× | ||
| Q3 25 | — | 20.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
